Nanoemulsion technology has taken one step closer to the market, with the announcement of a new licensing agreement between NanoBio, developer of the technology, and GlaxoSmthKline. The two companies have signed an exclusive over-the-counter licensing agreement for NanoBio’s nanoemulsion treatment, NB-001 for cold sores in the US and Canada. Under the agreement, GSK will pay NanoBio $14.5 million for licensing rights to NB- 001. NanoBio is eligible to receive additional milestone payments plus royalties on future sales.
TOP 5 ARTICLES FROM 2010
- Technology Connection: EMR Meets Modern Technology
Touch-screen technology may offer multiple benefits for adoption and effective use of EMRs.
By Michael Sherling, MD
- Recent Developments: What’s Next for the Dermatology Pharmaceutical Industry?
No doubt the dermatology pharmaceutical industry is undergoing a change. But what does it mean?
- Dermatology Q&A: New Directions in the Treatment of Hypopigmented Scars
A new study shows that off-label use of an unexpected agent yields promising results in the repigmentation of hypopigmented scars.
By Ted Pigeon, Senior Associate Editor
- Epidermal Barrier Dysfunction: Beyond Atopic Dermatitis
Specialists describe how a disrupted barrier contributes to common dermatoses and offer strategies for treatment.
By Joseph Bikowski, MD and Matthew Zirwas, MD
- Therapeutics Update